Aktuelle Aspekte der Lepra-Therapie

C. Bendick

doi:10.1055/s-2004-814281

Aktuelle Dermatologie, Table of Contents

Aktuelle Dermatologie 2004; 30(1/02): 30-35
DOI: 10.1055/s-2004-814281

Originalarbeit

Aktuelle Aspekte der Lepra-Therapie

Current Aspects of Leprosy TherapyC. Bendick¹

¹ University of Health Sciences, Department of Dermatology, Phnom Penh, Kambodscha

Abstract

Zusammenfassung

Die medikamentöse Therapie der Lepra hat in den letzten Jahrzehnten erhebliche Fortschritte gemacht. Vor dem Hintergrund der weltweiten Bemühungen um die Elimination der Erkrankung werden historische, gegenwärtige sowie neue und experimentelle Therapiestrategien erörtert und kritisch gewürdigt. Bedingungen für den künftigen Einsatz therapeutischer Regime sowie wesentliche Herausforderungen im Hinblick auf die medikamentöse Therapie der Lepra werden aufgezeigt.

Abstract

Drug therapy of leprosy has made great advances in the past decades. Regarding the worldwide efforts towards the elimination of the disease, historical, current and new, as well as experimental therapeutic strategies, are discussed and critically assessed. Conditions for the future application of therapeutic regimens, and essential challenges concerning the drug therapy of leprosy are elaborated.

Full Text

References

Literatur

1 World Health Assembly . Leprosy resolution 44.9. Forty-fourth World Health Assembly 13. 5. 1991
2 World Health Assembly .Press release World Health Assembly 54/2,. 16. 5. 2001
3 World Health Organization .The final push strategy to eliminate leprosy as a public health problem. Questions and answers. 2.Aufl. Genf; World Health Organization 2003
4 Lockwood D N. Leprosy elimination - a virtual phenomenon or a reality?. Brit Med J. 2002; 324 (7352) 1516-1518
5 Stearns A T. Leprosy: a problem solved by 2000. Lepr Rev. 2002; 73 (3) 215-224
6 Feenstra P. „Elimination” of leprosy and the need to sustain leprosy services, expectations, predictions and reality. Int J Lepr Other Mycobact Dis. 2003; 71 (3) 248-256
7 Yawalkar S J. Leprosy for Medical Practitioners and Paramedical Workers. 7. Auflage. Basel; Novartis Stiftung 2002
8 Faget G H, Pogge R C, Johansen F A, Dinan J F, Prejean B M, Eccles C G. The promin treatment of leprosy - a progress report. Pub Health Rep. 1943; 58 1729-1741
9 Fromm E, Wittmann J. Derivate des p-Nitrophenols. Berichte Deutsch Chem Ges. 1908; 41 2264-2273
10 Cochrane R, Ramanujam H, Paul H. et al . Two-and-a-half years experimental work on the sulphone group of drugs. Lepr Rev. 1949; 20 4-64
11 Lowe J. The late results of sulphone treatment of leprosy in East Nigeria. Lepr Rev. 1954; 25 (3) 13-124
12 Pettit J HS, Rees R JW. Sulphone resistance in leprosy. An experimental and clinical study. Lancet. 1964; II 673-674
13 Pearson J MH, Haile G S, Rees R JW. Primary dapsone-resistant leprosy. Lepr Rev. 1977; 48 (2) 129-132
14 WHO-Study Group .Chemotherapy of leprosy for control programmes. Tech Rep Ser 675. Genf; World Health Organization 1982
15 World Health Organization .Guide to Eliminate Leprosy as a Public Health Problem. WHO/CDS/CPE/CEE/2000.14. Genf; World Health Organization 2000
16 Georgiev G D, McDougall A C. Blister calendar packs - potential for the improvement in supply and utilization of multiple drug therapy in leprosy control programmes. Int J Lepr. 1988; 56 (4) 603-610
17 Huikeshoven H. Patient compliance in leprosy control: a necessity in old and new regimens. Int J Lepr. 1985; 53 (3) 474-480
18 Ridley D S, Jopling W H. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966; 34 (3) 255-273
19 WHO Expert Committee on Leprosy .6th Report. Tech Rep Ser 768. Genf; World Health Organization 1988
20 Goulart I M, Arbex G L, Carneiro M H, Rodrigues M S, Gadia R. [Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlandia]. Rec Soc Bras Med Trop. 2002; 35 (5) 453-460 (portugiesisch)
21 . Editorial. Adverse reactions to dapsone. Lancet. 1981; II 184-185
22 Rees R JW, Pearson J MH, Waters M FR. Experimental and clinical studies of rifampicin in treatment of leprosy. Brit Med J. 1970; 1 89-x
23 Leiker D L, Kamp H. First results of treatment of leprosy with Rifadin. Lepr Rev. 1970; 41 (1) 25-30
24 Languillon J, Yawalkar S J, McDougall A C. Therapeutic effect of adding rimactane (rifampicin) 450 milligrams daily or 1200 milligrams once monthly in a single dose to dapsone 50 milligrams daily in patients with lepromatous leprosy. Int J Lepr. 1979; 47 (1) 37-43
25 Browne S G, Hogerzeil L M. „B 663” in the treatment of leprosy. Preliminary report of a pilot trial. Lepr Rev. 1962; 33 6-10
26 Waters M FR. G 30 320 or B 663 - Lampren (Geigy). Lepr Rev. 1969; 40 (1) 21-47
27 Zimmerli-Ning M, Vischer W. A retrospective survey of the tolerability of clofazimine in patients with bacilliferous leprosy. Abstract III/137(A). New Delhi; XII. International Leprosy Congress 1984
28 Jacobson R R, Hastings R C. Rifampicin resistant leprosy. Lancet. 1976; II 1304-1305
29 Grosset J H, Guelpa-Lauras C C, Bobin P, Brucker G, Cartel J L, Constant-Desportes M, Flageul B, Frederic M, Guillaume J C, Millan J. Study of 39 documented relapses of multibacillary leprosy after treatment with rifampicin. Int J Lepr. 1989; 57 (3) 607-614
30 WHO Study Group .Chemotherapy of leprosy. Tech Rep Ser 874. Genf; World Health Organization 1998
31 Yoder L J, Jacobson R R, Hastings R C. The activity of rifabutin against Mycobacterium leprae. Lepr Rev. 1991; 62 (3) 280-287
32 Ji B, Grosset J. Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. Lepr Rev. 2000; 71 (Suppl.) S81-S87
33 Grosset J H. Newer drugs in leprosy. Int J Lepr Other Mycobakt Dis. 2001; 69 (Suppl.) S14-S18
34 Gelber R H. Successful treatment of a lepromatous patient with clarithromycin. Int J Lepr Other Mycobact Dis. 1995; 63 (1) 113-115
35 Ji B, Jamet P, Perani E G, Sow S, Lienhardt C, Petinon C, Grosset J H. Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Antimicrob Agents Chemother. 1996; 40 (9) 2137-2141
36 Ji B, Grosset J H. Ofloxacin for the treatment of leprosy. Acta Lepr. 1991; 7 (4) 321-326
37 Consigny S, Bentoucha A, Bonnafous P, Grosset J, Ji B. Bactericidal activities of HMR 3647, moxifloxacin and rifapentine against Mycobakterium leprae in mice. Antimicrob Agents Chemother. 2000; 44 (10) 2919-2921
38 Nakashima M, Uematsu T, Kanamaru M, Okazaki O, Hakusui H. Phase I study of levofloxacin,(s)-(-)-ofloxacin. Jpn J Clin Pharmacol Ther. 1992; 23 515-521
39 Dhople A M, Namba K. In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues. Int J Antimicrob Agents. 2003; 21 (3) 251-255
40 Bharti R. Pefloxacin in leprosy. Indian J Lepr. 1994; 66 (4) 443-448
41 Chan G P, Garcia-Ignacio B Y, Chavez V E, Livelo J B, Jimenez C L, Parrilla M L, Franzblau S G. Clinical trial of sparfloxacin for lepromatous leprosy. Antimicrob Agents Chemother. 1994; 38 (1) 61-65
42 Gelber R H, Fukuda K, Byrd S, Murray L P, Siu P, Tsang M, Rea T H. A clinical trial of minocycline in lepromatous leprosy. Brit Med J. 1992; 304 (6819) 91-92
43 WHO Expert Committee on Leprosy .7th Report. Tech Rep Ser 874. Genf; World Health Organization 1998
44 Single-Lesion Multicentre Trial Group . Efficacy of single dose multidrug therapy for treatment of single-lesion paucibacillary leprosy. Indian J Lepr. 1997; 69 (2) 121-129
45 Gupta M D. Field trials with a single dose of the combination rifampicin-ofloxacin-minocycline (ROM) for the treatment of paucibacillary leprosy. Lepr Rev. 2000; 71 (Suppl.) S77-S80
46 Ustianowski A P, Lockwood D NJ. Leprosy: current diagnostic and treatment approaches. Curr Opin Inf Dis. 2003; 16 (5) 421-427
47 Daumerie D. Current World Health Organization sponsored studies in the chemotherapy of leprosy. Lepr Rev. 2000; 71 (Suppl.) S88-S90
48 WHO-Study Group .Chemotherapy of leprosy for control programmes. Tech Rep Ser 675. Genf; World Health Organization 1982
49 WHO study group .Chemotherapy of leprosy. Report of a WHO study group. Tech Rep Ser 847. Genf; World Health Organization 1994
50 WHO Expert Committee on leprosy .Tech Rep Ser 874. Genf; World Health Organization 1998
51 Technical Advisory Group on elimination of leprosy .Report on third meeting of the WHO Conclusions and recommendations. Report No. WHO/CDS/CPE/CEE 2002.29. Genf; World Health Organization 2002
52 Ji B, Saunderson P. Uniform MDT (U-MDT) regimen for all leprosy patients: another example of wishful thinking. Lepr Rev. 2003; 74 (1) 2-6
53 World Health Organization .Guide to Eliminate Leprosy as a Public Health Problem. WHO/CDS/CPE/CEE/2000.14. Genf; World Health Organization 2000
54 Ji B. Accompanied MDT (AMDT) - more questions than answers. Lepr Rev. 2002; 73 (4) 301-307
55 Jacobson R R. Needed research in chemotherapy of leprosy related to the individual patient. Int J Lepr Other Mycobact Dis. 1996; 64 (Suppl.) S16-S20
56 Curtiss R 3rd, Blower S, Cooper K, Russell D, Silverstein S, Young L. Leprosy research in the post-genome era. Lepr Rev. 2001; 72 (1) 8-22
57 Ridley D S. Bacterial indices. In: Cochrane RG, Davey TF (Hrsg.) Leprosy in theory and practice. Bristol; 1964

1 Exazerbationen des ansonsten hoch chronischen Krankheitsverlaufes der Lepra werden als Reaktionen bezeichnet. Man unterscheidet die Typ I-Reaktion, welche durch einen - oftmals therapieinduzierten - Anstieg der zellvermittelten Immunität verursacht wird, von der Typ II-Reaktion (Erythema nodosum leprosum [ENL]), die man als ein durch Präzipitation von Ag/Ak-Komplexen verursachtes Immunkomplex-Syndrom auffasst. Typ I-Reaktionen kommen bei BT, BB- und BL-, selten auch bei TT-Fällen vor, Typ II-Reaktionen sind in aller Regel auf LL-, gelegentlich auch BL-Fälle beschränkt.

Dr. Christoph Bendick

Gotenring 33 · 50679 Köln

Email: soksabay@yahoo.com